Index of drugs

Active immunization against diphtheria, tetanus and pertussis of children from 7 weeks of age up to the age of 2, in accordance with the applicable Protective Vaccination Program. Children who have not been vaccinated at the dates recommended in the Protective Vaccination Program can be vaccinated with a preparation until they are 3 years of age, if there are no contraindications for pertussis vaccinations against whole pertussis. Vaccination can be performed: in disorders of the central nervous system with a chronic course, eg: cerebral palsy (without predisposition to convulsions), delayed mental development (without a tendency to convulsions), Down's syndrome; if contingent seizures have been detected in the past, but pharmacological cover and EEG assessment are recommended; in infants and children with diagnosed epilepsy, who have not had seizures for at least 12 months, as a result of treatment (vaccinations in this group should take place under the protection of previously used medicines); in infants, if family members have had convulsions or, possibly, vaccine reactions after vaccination with the preparation; in immunocompromised children, such as those associated with HIV infection, despite pathological changes, if it is possible to produce an answer even to a limited extent.

0.5 ml of the vaccine contains not less than 30 IU. diphtheria toxoid, not less than 40 IU tetanus toxoid and not less than 4 IU suspensionBordetella pertussis.

Tetanus-tetanus-pertussis vaccine, adsorbed combined, causing active immunity against diphtheria, tetanus and pertussis. The protective level of antibodies is obtained after primary vaccination, including 3 doses of primary vaccination and one dose of supplementary vaccination. Inactivated bacteria and toxoids (deprived of pathogenicity) trigger a response from the immune system consisting in the production of specific antibodies, activate the mechanisms of the formation of immunological memory. The immunizing properties of the vaccine are enhanced by the adjuvant action of aluminum hydroxide. The presence of a suspension of pertussis cells results in an additional adjuvant effect in relation to tokoxids.

Hypersensitivity to the components of the vaccine. acute febrile illness (mild infections are not a contraindication to administering a vaccine). Chronic diseases during the exacerbation period (in these cases, the vaccination should be performed after the exacerbation of the disease). Cerebral manifestations manifested by a consciousness disorder and focal neurological symptoms occurring within 72 hours after the previous vaccination. Convulsions with or without fever, occurring within 3 days after the previous dose of vaccine. An uninterrupted continuous cry or high-pitched cry (brain cry) lasting ≥ 3 hours, which occurred within 48 hours after the previous dose of vaccine. Loss of consciousness or hypotensive-hyporesponsive episode (within 7 days after the previous vaccination), which may have symptoms of cardio-respiratory disorders. Elevated body temperature ≥ 40.5 degrees C, not caused by other factors, occurring within 48 hours after the previous vaccination. If there are any contraindications for DTP vaccination - Adhesive diphtheria-tetanus-pertussis vaccine, the risk of administering the vaccine should be assessed against the risk of infection.

In patients undergoing immunosuppressive or immune deficiency therapy, the response to the vaccine may be reduced. In this case, it is recommended to postpone the vaccination until the end of therapy and to determine the level of antibodies after vaccination. The risk of apnea and the need to monitor respiratory function for 48 to 72 hours should be considered when administering primary vaccination doses to very premature premature babies (born ≤ 28 weeks of gestation), especially for those with signs of respiratory immaturity.Due to the significant benefits of vaccinating this group of infants, vaccination should not be withheld or deferred. The vaccine contains thiomersal as a preservative and therefore allergic reactions may occur in the vaccinated child. Make sure that the child has or has known allergic reactions and have any health problems after previous administration of the vaccine.

Not applicable - preparation for children.

Blood and lymphatic system disorders: enlargement and / or pain in lymph nodes. Immune system disorders: allergic reaction in the form of urticaria, rash (spotted, follicular or maculopapular), edema (including Quincke's edema), or anaphylactic shock. Metabolism and nutrition disorders: reduction or loss of appetite. Mental disorders: unmute continuous cry or scream of high tones (brain cry) lasting ≥ 3 hours, increased irritability - usually disappears within 24 - 48 hours, anxiety, apathy. Nervous system disorders: seizures with or without fever, maxillary thrombus, increase and then reduction of muscle tone (tension), hypotensive-hyporesponsive episode (hypotension, apathy, drowsiness, pallor and / or cyanosis) that may be associated with cardiorespiratory symptoms , disorders or loss of consciousness, encephalopathy, paresis of limb limb, which may be a symptom of brachial plexus inflammation, limitation of mobility and / or painfulness of the upper limb, reduction of muscle tone, hyperaesthesia, drowsiness, tremors. Vascular disorders: swelling or discoloration of the lower limbs (redness, bruising) sometimes accompanied by marbling of the skin or petechiae observed when co-administered with the preparation and vaccine againstHaemophilus influenzae type B and disappearing spontaneously without leaving persistent consequences, paleness, cyanosis, marbled skin, ecchymosis. Respiratory, thoracic and mediastinal disorders: apnea in very premature premature babies (born ≤ 28 weeks of gestation), breathing disorders, catarrh of the upper respiratory tract, cough, bronchitis. Gastrointestinal disorders: vomiting, diarrhea. Musculoskeletal and connective tissue disorders: chills. General disorders and administration site conditions: fever up to 39-40 ° C or above, local reactions: redness, pain, swelling (these symptoms usually disappear within 24 - 48 hours), decrease or loss of thirst. The presence of aluminum hydroxide in the vaccine may lead to subcutaneous nodules - granulomas, sometimes transforming into aseptic abscesses. The non-breaking grains in the 6-week period may be the result of developing hypersensitivity to aluminum.
Occasional: local reaction - redness of the skin, painful swelling at the injection site; general reaction - 38st.C - 39st.C fever, rarely up to 40 ° C, increased irritability. The presence of aluminum hydroxide in the vaccine may lead to subcutaneous nodules - granulomas, sometimes transforming into aseptic abscesses. The non-breaking grains in the 6-week period may be the result of developing hypersensitivity to aluminum.

Deep subcutaneously or intramuscularly (in the deltoid muscle or the anterior part of the thigh). Primary vaccination: 3 doses of 0.5 ml administered in the first 6 months of life, injection at 6-week intervals (the first dose in 2 months, the second dose at the turn of 3 and 4 months, the third dose in 5 months). Supplementary vaccination: 1 dose 0.5 ml in 2 years (in 16-18 months), in accordance with the applicable Protective Vaccine Program. After the vaccination, the child should remain under the doctor's supervision for 30 minutes.